Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Pfizer faces thousands of lawsuits linking Lipitor to type 2 diabetes

Posted: August 20, 2014

From the time the cholesterol-lowering statin Lipitor (atorvastatin) hit the market in 1996, it has been the No. 1 best-selling prescription drug in the country, bringing in more than $130 billion in worldwide sales. More than 29 million people in

Increased testosterone levels trigger aggression in male brain

Posted: August 20, 2014

Testosterone, the steroid hormone, has long been linked to aggressive behavior in men but, until now, it has been unclear the neural circuits through which testosterone exerts these effects. New research has identified for the first time that increasing levels of

Major depressive disorder drugs add warning for risk of rare eye disease

Posted: August 19, 2014

Drugs to treat major depressive disorder have been linked to angle-closure glaucoma, a rare type of the eye disease in which eye pressure rises very quickly, causing symptoms such as headache, eye pain, nausea, rainbows around lights at night, and

Young adults who were treated with growth hormones as children may be at greater risk for stroke

Posted: August 19, 2014

People who received growth hormones as children to treat short stature or hormone deficiency should be aware that they are at an increased risk of stroke caused by burst blood vessels when they become young adults, a team of French

New sleeping pill gets FDA approval, awaits DEA clearance

Posted: August 19, 2014

A new type of prescription sleep aid has won approval from the Food and Drug Administration (FDA) and if given clearance from the Drug Enforcement Administration (DEA) should be commercially available later this year.

Dialysis solutions recalled due to potential contamination

Posted: August 18, 2014

Baxter International is recalling two lots of Dianeal Low Calcium Peritoneal Dialysis Solution with 2.5 percent Dextrose 5000mL (Ambu-Flex II) because oxidized stainless steel, garment fiber and PVC particulate matter was present during the manufacturing process and seen floating in

AL Supreme Court rules: Brand name drug makers liable for warnings on generic drug counterparts

Posted: August 18, 2014

Makers of brand-name medications can be held liable for warnings on generic drugs even if the generic was produced by another drug company, the Alabama Supreme Court ruled. A majority of the nine-member court upheld a 2013 decision, which was

Lawsuits against Bayer alleging neurological side effects from Mirena IUD will not be centralized

Posted: August 15, 2014

Nine lawsuits against Bayer Healthcare Pharmaceuticals alleging the company’s Mirena IUD caused neurological conditions will not be consolidated into a multidistrict litigation because there are just too few to justify the motion. Plaintiffs had asked that the lawsuits be centralized

FDA approves new at-home colon cancer screening test

Posted: August 15, 2014

The Food and Drug Administration (FDA) has approved a new at-home stool sampling test that can detect colon cancer with more than 90 percent accuracy. The FDA gave unanimous approval to Exact Sciences Corp.’s Cologuard, a DNA-based test, finding it offered

Johnson and Johnson files motion to dismiss baby powder-ovarian cancer lawsuit

Posted: August 14, 2014

Johnson & Johnson filed a motion in Illinois court to dismiss a proposed class action lawsuit alleging the consumer health care company’s classic baby powder products increase the risk of ovarian cancer.